Figure 3 Methylation status of CCND2 promoter and correlation with expression of CCND2 mRNA. (A) In total, 55/118 (46.61%) hepatocellular carcinoma (HCC) patients, 8/47 (17.02%) liver cirrhosis (LC) patients, 8/75 (10.67%) chronic hepatitis B (CHB) patients, and 4/35 (11.43%) healthy controls (HCs) exhibited aberrant CCND2 promoter methylation in PBMCs. (B) 52/118 (44.07%) HCC patients, 5/47 (10.64%) LC patients, 7/75 (9.33%) CHB patients, and 2/35 (5.71%) HCs exhibited aberrant CCND2 promoter methylation in plasma. (C) CCND2 mRNA levels differed significantly between the methylation group and non-methylation groups (P<0.05). (D) Representative measurements of CCND2 promoter by methylation-specific polymerase chain reaction (MSP). PC – positive control; WB – water blank; M – methylated sequence; U – unmethylated sequence.